PB0796 - Interferon Treatment Suppresses in vitro NETosis in Neutrophils Derived from Patients with Myeloproliferative Neoplasms

Monday, June 26, 2023

18:30 – 19:30 ET

Room: Exhibition

Presenting Author(s)

IG

Idan Goldberg

Hematologist
Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
Petah Tikva, HaMerkaz, Israel

Co-Author(s)

SP

Shirly Partouche

Associate Researcher
Felsenstein Medical Research Center, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel.
Petah Tikva, HaMerkaz, Israel
EH

Erez Halperin

Hematologist
Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
Petah Tikva, HaMerkaz, Israel
BA

Bahaa Atamna

Hematologist
Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
Petah Tikva, HaMerkaz, Israel
AS

Adi Shacham-Abulafia

Hematologist
Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
Petah Tikva, HaMerkaz, Israel
Avi Leader, MD (he/him/his)

Hematologist
Institute of Hematology, Rabin Medical Center, Petah Tikva
Petah Tikva, HaMerkaz, Israel
Galia Spectre, MD PhD

Head of Thrombosis and Haemosasis Unit, Department of Hematology
Institute of Hematology, Rabin Medical Center, Petah Tikva
Petah Tikva, HaMerkaz, Israel
PR

Pia Raanani

Head of Institute of Hematology
Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
Petah Tikva, HaMerkaz, Israel
GG

Galit Granot

Head, Experimental Hematology Lab
Felsenstein Medical Research Center, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
Petah Tikva, HaMerkaz, Israel
OW

Ofir Wolach

Head, Hemato-oncology admission unit
Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
Petah Tikva, HaMerkaz, Israel

Background: During recent years, there has been an increased use of interferon as first or second lines of treatment for myeloproliferative neoplasms (MPN) mainly polycythemia vera (PV) and essential thrombocytosis (ET). Interferon treatment reduces erythrocytosis, thrombocytosis, spleen size and the rate of thrombotic and hemorrhagic complications. The mechanism by which interferon acts in MPN is not fully understood. Multiple factors affect the high tendency for thrombotic events in MPN patients. Several studies have demonstrated increased neutrophil extracellular traps (NETs) formation among patients with MPN. NETs formation (NETosis) might contribute to the thrombotic tendency in MPN. Thus, understanding the influence of cytoreductive therapy on NETosis might be of clinical interest.

Aims: We aim to evaluate the influence of interferon on NETosis of neutrophils derived from patients with MPN.

Methods: We enrolled untreated patients with MPN at a tertiary medical center. Neutrophils were harvested from all blood samples and were divided to plates that were incubated with interferon and to plates that were not exposed to interferon. NETosis was assessed by measurement of neutrophil elastase activity in all samples. Our results are being validated by cell death ELISA kit (Rosche) and by immunofluorescence staining.

Results: Ten patients (7 men and 3 women) with MPN were included in our cohort. MPN was PV in 6 patients, ET in 3 patients and unclassified in 1 patient. Among all 10 samples, the level of neutrophil elastase activity was significantly lower in samples that were incubated with interferon in comparison to samples that were not incubated with interferon (15.16mU/mL (±16.15) vs 17.13 mU/mL (±16.97), respectively (p=0.002)).

Conclusion(s): Our preliminary data suggest that interferon treatment reduces in-vitro NETosis of patients with MPN. Our results generate the hypothesis that the reduction in NETosis by interferon treatment contributes to its therapeutic effect in MPN. This hypothesis should be further investigated.